Daniel T. Michaeli

Heidelberg University - National Center for Tumor Diseases

Germany

SCHOLARLY PAPERS

10

DOWNLOADS

1,344

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (10)

1.

The Healthcare Workforce Shortage of Nurses and Physicians: Practice, Theory, Evidence, and Ways Forward

Number of pages: 26 Posted: 03 May 2022 Last Revised: 12 Dec 2023
Heidelberg University - National Center for Tumor Diseases, Heidelberg University - Department of Personalized Oncology, Technische Universität München (TUM) - Klinikum Rechts der Isar and Ludwig Maximilians University LMU University Hospital Munich
Downloads 687 (68,407)
Citation 2

Abstract:

Loading...

healthcare workforce; labour economics; physicians; nurses; medical education; labour supply; labour demand; health policy; health economics; labour policy; migration policy; labour migration; wage elasticity; rate of return

2.

Germany's Healthcare System: Funding, Resource Allocation, Provider Payment, Efficiency, and Access

Number of pages: 14 Posted: 17 May 2022
Daniel T. Michaeli, Hasan Yagmur and Thomas Michaeli
Heidelberg University - National Center for Tumor Diseases, affiliation not provided to SSRN and Heidelberg University - Department of Personalized Oncology
Downloads 230 (235,800)
Citation 1

Abstract:

Loading...

healthcare system; healthcare financing; private health insurance; patient access; efficiency; resource allocation; equity; public health insurance; health policy; health economics; Germany

3.

Medical Savings Accounts: Implications on Healthcare Expenditure, Efficiency, Equity, and Financial Protection

Number of pages: 12 Posted: 17 May 2022
Daniel T. Michaeli, Tobias Boch and Thomas Michaeli
Heidelberg University - National Center for Tumor Diseases, University Hospital Mannheim and Heidelberg University - Department of Personalized Oncology
Downloads 84 (521,980)
Citation 1

Abstract:

Loading...

medical savings account; health savings account; healthcare expenditure; healthcare financing; inequity; financial protection; health insurance; health policy; health economics; financial protection; personal bankruptcy

4.

Cancer Drug Prices in the US: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology

Value Health. 2023 Nov; 26(11):1590-1600. doi: 10.1016/j.jval.2023.06.020. Epub 2023 Jul 28. PMID: 37516196.
Number of pages: 49 Posted: 20 Apr 2023 Last Revised: 19 Dec 2023
Daniel T. Michaeli and Thomas Michaeli
Heidelberg University - National Center for Tumor Diseases and Heidelberg University - Department of Personalized Oncology
Downloads 67 (592,991)
Citation 1

Abstract:

Loading...

drug prices; cancer drugs; overall survival; progression-free survival; clinical trials; drug development; DALY; unmet needs; indication-specific pricing; value-based pricing; multiple indications

5.

Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs

Number of pages: 29 Posted: 18 Aug 2023 Last Revised: 12 Dec 2023
Daniel T. Michaeli and Thomas Michaeli
Heidelberg University - National Center for Tumor Diseases and Heidelberg University - Department of Personalized Oncology
Downloads 57 (648,089)

Abstract:

Loading...

cancer drug; healthcare expenditure; partial orphans; ultra-rare orphans; common orphans; rare diseases; drug pricing; Medicare; Medicaid; indication-specific pricing; weighted-average pricing; value-based pricing; cost; budget impact; cost control

6.

Association Between Clinical Trial Design Characteristics and Treatment Effect Estimates: A Meta-analysis of Randomized-Controlled and Single-Arm Trials Supporting the FDA Approval of 455 New Cancer Drugs and Indications

Number of pages: 29 Posted: 26 Aug 2023
Heidelberg University - National Center for Tumor Diseases, Heidelberg University - Department of Personalized Oncology, Technische Universität München (TUM) - Klinikum Rechts der Isar and Ludwig Maximilians University LMU University Hospital Munich
Downloads 55 (676,131)
Citation 1

Abstract:

Loading...

clinical trials; cancer drugs; trial design; FDA; randomized-controlled trials; single-arm trials; overall survival; progression-free survival; tumor response; meta-analysis; drug development

7.

Clinical Benefit, Development, Innovativeness, Trials, Epidemiology, and Price for Cancer Drugs and Indications with Multiple Special FDA Designations

Number of pages: 33 Posted: 18 Aug 2023
Heidelberg University - National Center for Tumor Diseases, Heidelberg University - Department of Personalized Oncology, Technische Universität München (TUM) - Klinikum Rechts der Isar and Ludwig Maximilians University LMU University Hospital Munich
Downloads 48 (693,976)
Citation 1

Abstract:

Loading...

cancer drugs; orphan; breakthrough; accelerated approval; fast track; priority review; overall survival; progression-free survival; clinical trial; unmet need; drug price

8.

Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases

Number of pages: 8 Posted: 18 Apr 2023
Daniel T. Michaeli and Thomas Michaeli
Heidelberg University - National Center for Tumor Diseases and Heidelberg University - Department of Personalized Oncology
Downloads 44 (725,698)

Abstract:

Loading...

orphan designation; cancer drug; healthcare expenditure; common orphans; rare orphans; ultra-rare orphans

9.

Partial Orphan Cancer Drugs: FDA Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending

Number of pages: 34 Posted: 18 Aug 2023
Daniel T. Michaeli and Thomas Michaeli
Heidelberg University - National Center for Tumor Diseases and Heidelberg University - Department of Personalized Oncology
Downloads 43 (725,698)
Citation 3

Abstract:

Loading...

Orphan designation; cancer drug; clinical trial; epidemiology; price; drug development; overall survival; partial orphan; drug spending; Medicare; Medicaid; progression-free survival; rare diseases

10.

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

Number of pages: 23 Posted: 18 Aug 2023
Heidelberg University - National Center for Tumor Diseases, Heidelberg University - Department of Personalized Oncology, Technische Universität München (TUM) - Klinikum Rechts der Isar and Ludwig Maximilians University LMU University Hospital Munich
Downloads 29 (829,750)

Abstract:

Loading...

cancer drugs; accrual; orphan; ultra-orphan; clinical trials; drug development; DALY; unmet needs